Alligator Bioscience AB (ATORX)

Currency in SEK
1.0180
-0.0298(-2.84%)
Real-time Data·
ATORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.00501.0498
52 wk Range
0.00667.4000
Key Statistics
Prev. Close
1.0478
Open
1.0498
Day's Range
1.005-1.0498
52 wk Range
0.0066-7.4
Volume
62.65K
Average Volume (3m)
1.1M
1-Year Change
2,040.38%
Book Value / Share
-0.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATORX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Alligator Bioscience AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Alligator Bioscience AB Company Profile

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.

Alligator Bioscience AB Earnings Call Summary for Q3/2025

  • Stock plummets 46.36% post-earnings, closing at 2.7 SEK amid financial concerns and rights issue dilution
  • Secures 65% of 120M SEK rights issue, aiming to extend financial runway into 2026; operating costs at 17M SEK for Q3
  • Mitazalimab shows promising 30-month survival data in pancreatic cancer; multiple phase II studies planned for Q4 2025
  • CEO highlights ongoing partnership discussions for mitazalimab development; financial health score rated as WEAK
  • Projected quarterly costs between 15-20M SEK; company faces execution risks in clinical trials and competitive pressures
Last Updated: 23/10/2025, 15:04
Read Full Transcript

Compare ATORX to Peers and Sector

Metrics to compare
ATORX
Peers
Sector
Relationship
P/E Ratio
−0.6x−19.6x−0.6x
PEG Ratio
−0.010.000.00
Price/Book
−5.0x8.4x2.6x
Price / LTM Sales
1.0x18.6x3.3x
Upside (Analyst Target)
-61.7%45.2%
Fair Value Upside
Unlock7.6%7.0%Unlock

Earnings

Latest Release
Oct 23, 2025
EPS / Forecast
-0.34 / --
Revenue / Forecast
384.00K / --
EPS Revisions
Last 90 days

ATORX Income Statement

FAQ

What Stock Exchange Does Alligator Bioscience Trade On?

Alligator Bioscience is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Alligator Bioscience?

The stock symbol for Alligator Bioscience is "ATORX."

What Is the Alligator Bioscience Market Cap?

As of today, Alligator Bioscience market cap is 45.96M.

What Is Alligator Bioscience's Earnings Per Share (TTM)?

The Alligator Bioscience EPS (TTM) is -4.70.

When Is the Next Alligator Bioscience Earnings Date?

Alligator Bioscience will release its next earnings report on 11 Feb 2026.

From a Technical Analysis Perspective, Is ATORX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Alligator Bioscience Stock Split?

Alligator Bioscience has split 2 times.

How Many Employees Does Alligator Bioscience Have?

Alligator Bioscience has 13 employees.

What is the current trading status of Alligator Bioscience (ATORX)?

As of 20 Nov 2025, Alligator Bioscience (ATORX) is trading at a price of 1.0180, with a previous close of 1.0478. The stock has fluctuated within a day range of 1.0050 to 1.0498, while its 52-week range spans from 0.0066 to 7.4000.

What Is Alligator Bioscience (ATORX) Price Target According to Analysts?

The average 12-month price target for Alligator Bioscience is SEK19, with a high estimate of SEK19 and a low estimate of SEK19. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,766.40% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.